MCID: BCT013
MIFTS: 55

Bacterial Pneumonia

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Bacterial Pneumonia

Summaries for Bacterial Pneumonia

Disease Ontology : 12 A pneumonia involving inflammation of the lungs caused by bacteria.

MalaCards based summary : Bacterial Pneumonia, also known as pneumonia due to other gram-negative bacteria, is related to mycoplasma pneumoniae pneumonia and adult respiratory distress syndrome. An important gene associated with Bacterial Pneumonia is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Levofloxacin and Ceftaroline fosamil have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and neutrophil, and related phenotype is respiratory system.

Wikipedia : 77 Bacterial pneumonia is a type of pneumonia caused by bacterial... more...

Related Diseases for Bacterial Pneumonia

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Bacterial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 mycoplasma pneumoniae pneumonia 32.7 CRP IL17A IL6
2 adult respiratory distress syndrome 30.2 CXCL8 ELANE IL6 SFTPB
3 viral pneumonia 30.0 CRP IL17A IL6
4 bacterial meningitis 30.0 CRP CXCL8 IL6
5 endocarditis 30.0 CRP CXCL8 IL6 LACTB
6 acute respiratory distress syndrome 29.9 CXCL8 ELANE IL6 SFTPB SFTPD
7 avian influenza 29.8 CXCL8 IL6 SFTPD
8 deficiency anemia 29.8 CRP CSF3 IL6
9 bronchitis 29.8 CRP CXCL8 ELANE LACTB
10 interstitial lung disease 29.6 CXCL8 IL6 SFTPB SFTPD
11 peritonitis 29.5 ADA CRP CXCL8 IL6
12 aspergillosis 29.5 ELANE SFTPD TLR4
13 chlamydia 29.4 CRP CXCL8 IL6 TLR4
14 pneumonia 29.3 CCL3 CRP CSF3 CXCL1 CXCL8 ELANE
15 kaposi sarcoma 29.2 CXCL1 CXCL8 IL6
16 respiratory failure 29.1 CRP CXCL8 ELANE SCGB1A1 SFTPB SFTPD
17 newborn respiratory distress syndrome 29.1 CXCL8 ELANE IL6 SCGB1A1 SFTPB SFTPD
18 human immunodeficiency virus type 1 29.0 ADA CCL3 CXCL1 IL6
19 periodontal disease 28.9 CRP CXCL8 DEFB4A ELANE IL17A IL6
20 meningitis 28.8 ADA CCL3 CRP CXCL1 CXCL8 IL6
21 lung disease 28.8 CCL3 CXCL8 ELANE IL17A IL6 SFTPB
22 asthma 28.6 CCL3 CXCL1 CXCL8 ELANE IL17A IL6
23 malaria 28.6 CCL3 CRP CSF3 CXCL8 IL17A IL6
24 pulmonary disease, chronic obstructive 28.4 CRP CXCL8 ELANE IL17A IL6 SCGB1A1
25 bacterial infectious disease 28.3 CRP CSF3 CXCL8 DEFB4A ELANE IL17A
26 influenza 11.5
27 klebsiella pneumonia 11.4
28 pleural empyema 11.4
29 chlamydia pneumonia 11.1
30 streptococcus pneumonia 11.1
31 aspiration pneumonia 11.1
32 myasthenic syndrome, congenital, 1a, slow-channel 10.4 CRP CXCL8
33 engraftment syndrome 10.4 CSF3 CXCL8
34 recurrent corneal erosion 10.4 CXCL8 IL6
35 cold agglutinin disease 10.4 CRP IL6
36 bagassosis 10.4 CXCL8 IL6
37 acute transverse myelitis 10.4 CXCL8 IL6
38 streptococcal toxic-shock syndrome 10.4 CXCL8 IL6
39 cryopyrin-associated periodic syndrome 10.4 CRP IL6
40 cyclic neutropenia 10.4 CSF3 CXCL8 ELANE
41 pyuria 10.4 CRP CXCL8
42 paraquat lung 10.4 SCGB1A1 SFTPB
43 mycobacterium fortuitum 10.4 CXCL8 LACTB
44 pyomyositis 10.4 CRP GPT
45 cardiac rupture 10.4 CRP CXCL8 ELANE
46 acute cholangitis 10.4 CRP IL6
47 capillary leak syndrome 10.3 CXCL8 ELANE IL6
48 louse-borne relapsing fever 10.3 CRP CXCL8 IL6
49 viral meningitis 10.3 CRP CXCL8 IL6
50 denture stomatitis 10.3 CXCL8 IL6

Graphical network of the top 20 diseases related to Bacterial Pneumonia:



Diseases related to Bacterial Pneumonia

Symptoms & Phenotypes for Bacterial Pneumonia

MGI Mouse Phenotypes related to Bacterial Pneumonia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 ADA IL17A IL6 SCGB1A1 SFTPB SFTPD

Drugs & Therapeutics for Bacterial Pneumonia

Drugs for Bacterial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
2
Ceftaroline fosamil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 229016-73-3
3
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
4
Vancomycin Approved Phase 4,Phase 3,Phase 2 1404-90-6 14969 441141
5
Ceftriaxone Approved Phase 4,Phase 3,Phase 2 73384-59-5 5479530 5361919
6
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 26787-78-0 33613
7
Linezolid Approved, Investigational Phase 4,Phase 3,Phase 2 165800-03-3 441401
8
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
9
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
10
Zidovudine Approved Phase 4,Phase 3 30516-87-1 35370
11
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
12
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
13
Nevirapine Approved Phase 4 129618-40-2 4463
14
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
15
Ribavirin Approved Phase 4 36791-04-5 37542
16
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
18
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
19
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Cephalosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
24 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
25 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
26 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
27 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Phase 1
29 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 methicillin Phase 4,Phase 3
33 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Clindamycin palmitate Phase 4
35 beta-Lactamase Inhibitors Phase 4,Phase 3,Phase 2
36 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 2,Phase 3
37 Clindamycin phosphate Phase 4
38 Clavulanic Acids Phase 4,Phase 2,Phase 3
39 MF59 oil emulsion Phase 4
40 Vaccines Phase 4,Not Applicable
41 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
42 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
43 Anti-Retroviral Agents Phase 4,Phase 3,Not Applicable
44 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4,Phase 3
45 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Antimetabolites Phase 4,Phase 3
47 Vitamins Phase 4,Not Applicable
48 Ergocalciferols Phase 4,Not Applicable
49 Bone Density Conservation Agents Phase 4,Not Applicable
50 Hormones Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia Completed NCT01524302 Phase 4 Ceftaroline;Levofloxacin
2 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus Completed NCT01645735 Phase 4 Ceftaroline fosamil;Ceftriaxone plus vancomycin
3 Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP) Completed NCT01669980 Phase 4 Ceftaroline fosamil;IV Ceftriaxone and Vancomycin
4 Adjuvanted Influenza Vaccine in Stem Cell Transplant Completed NCT02560909 Phase 4
5 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects Completed NCT00634569 Phase 4
6 Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals Active, not recruiting NCT03723525 Phase 4
7 Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED) Terminated NCT00687544 Phase 4 Ribavirin (SCH 018908)
8 Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients Terminated NCT01817699 Phase 4
9 Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia Withdrawn NCT01666743 Phase 4 Ceftaroline fosamil
10 A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Unknown status NCT01937832 Phase 3 Faropenem;Ertapenem
11 The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Unknown status NCT01865266 Phase 2, Phase 3 Ulinaststin for injection;placebo
12 Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Unknown status NCT01581593 Phase 3
13 A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Completed NCT01371838 Phase 3 Ceftaroline;Ceftriaxone
14 Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) Completed NCT02493764 Phase 3 Imipenem;Relebactam;Cilastatin;Piperacillin;Tazobactam;Linezolid
15 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia Completed NCT02679573 Phase 3 Delafloxacin;Moxifloxacin;Linezolid
16 Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Completed NCT01968733 Phase 3 Solithromycin;Moxifloxacin
17 Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Completed NCT01756339 Phase 3 Solithromycin;Moxifloxacin
18 Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia Completed NCT01605864 Phase 3 Efficacy of ceftaroline
19 A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia Completed NCT01561794 Phase 3 Ciprofloxacin (Cipro, BAYQ3939)
20 Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Completed NCT01530763 Phase 2, Phase 3 Ceftaroline fosamil;Ceftriaxone;amoxicillin clavulanate
21 Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Completed NCT00538694 Phase 3 daptomycin
22 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Completed NCT02531438 Phase 3 Omadacycline;Moxifloxacin
23 Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00540072 Phase 3 daptomycin
24 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia Completed NCT02813694 Phase 3 lefamulin;Moxifloxacin
25 Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Completed NCT02559310 Phase 3 lefamulin;Moxifloxacin;Linezolid
26 Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens Completed NCT03032380 Phase 3 S-649266;Meropenem;Linezolid
27 Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00081575 Phase 3 Tigecycline;Levofloxacin
28 Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Completed NCT00079885 Phase 3 tigecycline
29 Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
30 Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
31 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00124020 Phase 3 Telavancin;Vancomycin
32 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00107952 Phase 3 Telavancin;Vancomycin
33 Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Completed NCT00080496 Phase 3 Tigecycline;Imipenem;Cilastatin
34 Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) Completed NCT02070757 Phase 3 ceftolozane/tazobactam;Meropenem
35 Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB) Completed NCT01292031 Phase 3 Colistin;Meropenem
36 A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
37 Study of Fluid Collection of the Chest in Children With Pneumonia Completed NCT00202826 Phase 3
38 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
39 Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Completed NCT01868113 Phase 3 Inhaled corticosteroid
40 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) Completed NCT02452047 Phase 3 Imipenem+Cilastatin/Relebactam;Colistimethate sodium (CMS);Imipenem+Cilastatin;Placebo to CMS
41 Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial) Completed NCT01717742 Phase 3 tPA;DNase
42 Tedizolid Phosphate (TR-701 FA) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) Completed NCT02019420 Phase 3 Tedizolid phosphate IV;Linezolid
43 A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients Completed NCT00000991 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Dapsone;Zidovudine
44 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) Completed NCT00538915 Phase 3
45 Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze Completed NCT00407394 Phase 3 Amoxycillin
46 A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases Completed NCT01012323 Phase 3
47 Immune Globulin Subcutaenous (Human), 20% Completed NCT01412385 Phase 2, Phase 3
48 Gammagard Liquid and rHuPH20 in PID Completed NCT00814320 Phase 3
49 Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study) Completed NCT01461018 Phase 3
50 The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) Completed NCT01189487 Phase 3 ampicillin sodium/sulbactam sodium

Search NIH Clinical Center for Bacterial Pneumonia

Cochrane evidence based reviews: pneumonia, bacterial

Genetic Tests for Bacterial Pneumonia

Anatomical Context for Bacterial Pneumonia

MalaCards organs/tissues related to Bacterial Pneumonia:

42
Lung, Skin, Neutrophil, Testes, Liver, Bone, Colon

Publications for Bacterial Pneumonia

Articles related to Bacterial Pneumonia:

(show top 50) (show all 640)
# Title Authors Year
1
Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points. ( 31041348 )
2019
2
A Comparison of the Mortality Risk Associated With Ventilator-Acquired Bacterial Pneumonia and Nonventilator ICU-Acquired Bacterial Pneumonia. ( 30407949 )
2019
3
The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. ( 30596308 )
2019
4
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. ( 30649434 )
2019
5
ABL kinase inhibition promotes lung regeneration through expansion of an SCGB1A1+ SPC+ cell population following bacterial pneumonia. ( 30655340 )
2019
6
Recurrent bacterial pneumonia in Irish Wolfhounds: Clinical findings and etiological studies. ( 30666726 )
2019
7
Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). ( 30670415 )
2019
8
Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial. ( 30722059 )
2019
9
Omadacycline for Community-Acquired Bacterial Pneumonia. ( 30726692 )
2019
10
A spatial analysis of geographic variation and factors associated with hospitalization for bacterial pneumonia in Korea. ( 30786908 )
2019
11
Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: a meta-analysis of randomized controlled trials. ( 30810253 )
2019
12
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). ( 30843070 )
2019
13
Computational screening of potential drug targets for pathogens causing bacterial pneumonia. ( 30914386 )
2019
14
Risk of bacterial pneumonia and pneumococcal infection in youths with celiac disease - A population-based study. ( 30926284 )
2019
15
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia. ( 30949705 )
2019
16
Mind the Coverage Gap: A PK-PD Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. ( 30962339 )
2019
17
Can Nebulised Colistin Therapy Improve Outcomes in Critically Ill Children with Multi-Drug Resistant Gram-Negative Bacterial Pneumonia? ( 30979085 )
2019
18
Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective. ( 30996766 )
2019
19
Aberrant Th2 inflammation drives dysfunction of alveolar macrophages and susceptibility to bacterial pneumonia. ( 28260794 )
2018
20
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). ( 28851249 )
2018
21
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. ( 29020279 )
2018
22
Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. ( 29038277 )
2018
23
The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. ( 29396891 )
2018
24
Bacterial Pneumonia in Elderly Japanese Populations. ( 29434484 )
2018
25
Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus. ( 29454592 )
2018
26
Recurrent bacterial pneumonia due to immunoglobulin G2 subclass deficiency after allogeneic hematopoietic stem cell transplantation: Efficacy of immunoglobulin replacement. ( 29512243 )
2018
27
SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. ( 29514266 )
2018
28
15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-κB Regulators in Bacterial Pneumonia. ( 29523657 )
2018
29
Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice. ( 29543040 )
2018
30
Early Bacterial Pneumonia After Hepatic Transplantation: Epidemiologic Profile. ( 29579836 )
2018
31
Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia". ( 29588353 )
2018
32
Bacterial pneumonia in kidney transplant recipients. ( 29605219 )
2018
33
Inhibition of IP6K1 suppresses neutrophil-mediated pulmonary damage in bacterial pneumonia. ( 29618559 )
2018
34
Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. ( 29621339 )
2018
35
Secondary Bacterial Pneumonia by Staphylococcus aureus Following Influenza A Infection Is SaeR/S Dependent. ( 29668950 )
2018
36
Lectin Microarray Combined with Mass Spectrometry Identifies Haptoglobin-Related Protein (HPR) as a Potential Serologic Biomarker for Separating Nonbacterial Pneumonia from Bacterial Pneumonia in Childhood. ( 29785832 )
2018
37
Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department. ( 29789175 )
2018
38
Community-acquired bacterial pneumonia in adult HIV-infected patients. ( 29976111 )
2018
39
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia. ( 30010650 )
2018
40
Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. ( 30055898 )
2018
41
C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. ( 30107791 )
2018
42
Laboratory Investigation of Trends in Bacterial Pneumonia in Cheonan, Korea, from January 2008 to September 2017. ( 30178647 )
2018
43
Corrigendum: Elucidation of Bacterial Pneumonia-Causing Pathogens in Patients with Respiratory Viral Infection. ( 30238717 )
2018
44
Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. ( 30315990 )
2018
45
CCR2 mediates increased susceptibility to post-H1N1 bacterial pneumonia by limiting dendritic cell induction of IL-17. ( 30498200 )
2018
46
Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia. ( 30505304 )
2018
47
YKL-40 levels are associated with disease severity and prognosis of viral pneumonia, but not available in bacterial pneumonia in children. ( 30514252 )
2018
48
Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia. ( 30619303 )
2018
49
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. ( 27510635 )
2017
50
Solithromycin for the treatment of community-acquired bacterial pneumonia. ( 27753516 )
2017

Variations for Bacterial Pneumonia

Expression for Bacterial Pneumonia

Search GEO for disease gene expression data for Bacterial Pneumonia.

Pathways for Bacterial Pneumonia

Pathways related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCL3 CRP CSF3 CXCL1 CXCL8 DEFB4A
2
Show member pathways
13.58 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
3
Show member pathways
13.32 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
4
Show member pathways
13.28 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
5
Show member pathways
13.22 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
6
Show member pathways
13.02 CCL3 CXCL1 CXCL8 IL6 SFTPD TLR4
7
Show member pathways
12.49 IL17A IL22 IL6 TLR4
8
Show member pathways
12.18 CSF3 CXCL1 CXCL8 DEFB4A IL17A IL6
9
Show member pathways
12.09 CXCL8 DEFB4A IL6 SFTPD TLR4
10
Show member pathways
12.01 CCL3 CXCL8 IL17A IL22 IL6
11
Show member pathways
12.01 IL17A IL22 IL6 TLR4
12 11.95 CXCL1 CXCL8 IL6 TLR4
13
Show member pathways
11.89 CCL3 CXCL1 CXCL8
14 11.88 CXCL8 IL17A IL6
15 11.87 CCL3 CXCL1 CXCL8 IL6
16 11.82 CXCL1 CXCL8 IL6 TLR4
17 11.71 CCL3 IL17A IL22
18 11.68 CXCL8 IL6 TLR4
19 11.66 CCL3 CXCL1 IL17A IL6
20 11.65 CCL3 CXCL1 CXCL8 IL6 TLR4
21 11.6 CCL3 CSF3 CXCL8 IL6
22
Show member pathways
11.6 CSF3 CXCL1 CXCL8 IL17A IL6 TLR4
23 11.5 CXCL1 CXCL8 IL6 TLR4
24 11.4 CSF3 CXCL8 IL6 TLR4
25 11.39 CCL3 CXCL1 CXCL8 IL17A IL6 TLR4
26 11.34 CCL3 CSF3 CXCL1 CXCL8 IL6
27 11.27 IL17A IL22 IL6
28 11.2 CSF3 CXCL1 IL6
29 10.98 CRP CXCL8 IL6
30 10.88 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
31 10.4 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22

GO Terms for Bacterial Pneumonia

Cellular components related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 CCL3 CRP CSF3 CXCL1 CXCL8 DEFB4A
2 extracellular space GO:0005615 9.5 ADA CCL3 CRP CSF3 CXCL1 CXCL8

Biological processes related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.83 DEFB4A ELANE SFTPD TLR4
2 regulation of signaling receptor activity GO:0010469 9.8 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
3 defense response to Gram-positive bacterium GO:0050830 9.76 CRP DEFB4A IL6
4 immune response GO:0006955 9.76 CCL3 CSF3 CXCL1 CXCL8 DEFB4A IL17A
5 defense response to Gram-negative bacterium GO:0050829 9.74 DEFB4A IL6 TLR4
6 neutrophil chemotaxis GO:0030593 9.73 CCL3 CXCL1 CXCL8
7 chemotaxis GO:0006935 9.73 CCL3 CXCL1 CXCL8 DEFB4A
8 cellular response to interleukin-1 GO:0071347 9.72 CCL3 CXCL8 IL17A
9 cellular response to lipopolysaccharide GO:0071222 9.72 CSF3 CXCL1 CXCL8 IL6 TLR4
10 chemokine-mediated signaling pathway GO:0070098 9.67 CCL3 CXCL1 CXCL8
11 response to glucocorticoid GO:0051384 9.65 IL22 IL6 SCGB1A1
12 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.63 CXCL1 CXCL8 DEFB4A
13 positive regulation of chemokine production GO:0032722 9.61 IL6 TLR4
14 embryonic digestive tract development GO:0048566 9.61 ADA CXCL8
15 positive regulation of calcium-mediated signaling GO:0050850 9.6 ADA CCL3
16 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 IL17A TLR4
17 macrophage chemotaxis GO:0048246 9.58 CCL3 SFTPD
18 acute-phase response GO:0006953 9.58 CRP IL22 IL6
19 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.54 ELANE TLR4
20 negative regulation of lipid storage GO:0010888 9.51 CRP IL6
21 cytokine-mediated signaling pathway GO:0019221 9.5 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
22 negative regulation of chemokine biosynthetic process GO:0045079 9.37 ELANE IL6
23 inflammatory response GO:0006954 9.23 CCL3 CRP CXCL1 CXCL8 IL17A IL22

Molecular functions related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL3 CSF3 CXCL1 CXCL8 IL17A IL22
2 chemokine activity GO:0008009 9.13 CCL3 CXCL1 CXCL8

Sources for Bacterial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....